CDK5 and Parkinson disease: Pharmacological inhibition of CDK5 suppressed USP30 upregulation, attenuated MAVS pathway activation, and exerted protective effects in both in vitro (MPP+ -treated neuronal cells) and in vivo (MPTP-induced mouse) PD models.